Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Venetoclax Combining with Homoharringtonine，Daunorubicin and Cytarabine (HAD) As Induction Treatment in Newly Diagnosed Adult Acute Myeloid Leukemia Patients

Zhangsong Yan, Yang Li, Bin Zhang, Jinsong He, Jiesi Li, Shuning Wei, Qi Wang, Qiuling Li, Bo Hu, Kaiqi Liu, Yingchang Mi

Blood (2023) 142 (Supplement 1): 2895.

https://doi.org/10.1182/blood-2023-179087

Published: 2023

Journal Articles

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Wei Liu, Yi Wang, Yan Xu, Chenxing Du, Qi Wang, Tingyu Wang, Wenyang Huang, Shuaishuai Zhang, Shuhua Yi, Yuting Yan, Tengteng Yu, Weiwei Sui, Gang An, Rui Lyu, Huimin Liu, Wenjie Xiong, Mingwei Fu, Dehui Zou, Lugui Qiu

Blood (2023) 142 (Supplement 1): 6232.

https://doi.org/10.1182/blood-2023-185669

Published: 2023

Journal Articles

The Incidence, Clinical Application and Prognostic Significance of MYD88 and CXCR4 Mutation in Chinese Patients with Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia

Ying Yu, Yuting Yan, Jun Wang, Wenjie Xiong, Yao Yao, Yanshan Huang, Rui Lyu, Tingyu Wang, Qi Wang, Wei Liu, Gang An, Weiwei Sui, Yan Xu, Wenyang Huang, Dehui Zou, Zhijian Xiao, Lugui Qiu, Shuhua Yi

Blood (2023) 142 (Supplement 1): 6089.

https://doi.org/10.1182/blood-2023-188786

Published: 2023

Journal Articles

The Prognostic Impact of Measurable Residual Disease Dynamics in Mantle Cell Lymphoma

Yanshan Huang, Yuting Yan, Ying Yu, Li Yuxi, Rui Lv, Tingyu Wang, Wenjie Xiong, Qi Wang, Wei Liu, Gang An, Weiwei Sui, Yan Xu, Wenyang Huang, Dehui Zou, Lugui Qiu, Shuhua Yi

Blood (2023) 142 (Supplement 1): 3038.

https://doi.org/10.1182/blood-2023-188881

Published: 2023

Journal Articles

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Li Yuxi, Ying Yu, Yanshan Huang, Rui Cui, Jingwen Sun, Rui Lyu, Tingyu Wang, Wenjie Xiong, Yuting Yan, Qi Wang, Wei Liu, Gang An, Weiwei Sui, Yan Xu, Wenyang Huang, Dehui Zou, Lugui Qiu, Shuhua Yi

Blood (2023) 142 (Supplement 1): 1649.

https://doi.org/10.1182/blood-2023-186068

Published: 2023

Journal Articles

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

Blood (2023) 142 (Supplement 1): 6864.

https://doi.org/10.1182/blood-2023-184868

Published: 2023

Journal Articles

Population Pharmacokinetic-Pharmacodynamic Modeling of Neutrophil and Platelet Count for Lower-Intensity Therapy of CPX-351 Combined with Venetoclax in Acute Myeloid Leukemia

Yali Liang, Sarah F Cook, Ronald Cheung, Honghui Zhou, Sheryl Coppola, Qi Wang, Donald E Mager, Scott A Van Wart

Blood (2023) 142 (Supplement 1): 2902.

https://doi.org/10.1182/blood-2023-182111

Published: 2023

Journal Articles

Good Survival of CAR-T Cell Therapy Bridging to Allo-HSCT for Relapsed/Refractory Ph-Positive B-Cell Acute Lymphoblastic Leukemia

Zhanxiang Liu, Tong Wu, Yanzhi Song, Erhui Yuan, Qishu Qin, Qi Wang

Blood (2023) 142 (Supplement 1): 7043.

https://doi.org/10.1182/blood-2023-187988

Published: 2023

Journal Articles

First-in-Human Study of Elvn-001, a Highly Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients with Chronic Myeloid Leukemia Who Failed Previous Tyrosine Kinase Inhibitor Therapies

Timothy Hughes, Michael Mauro, Susan Branford, Wei Deng, Qi Wang, Helen Collins, Andreas Hochhaus

Blood (2022) 140 (Supplement 1): 6780–6781.

https://doi.org/10.1182/blood-2022-170401

Published: 2022

Journal Articles

Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK + anaplastic large cell lymphoma

Blood (2022) 139 (5): 717–731.

https://doi.org/10.1182/blood.2020008136

Published: 2022

Includes: Supplemental data

Journal Articles

CPX-351, a Dual-Drug Liposomal Formulation, Alleviates the Cardiotoxicity of Daunorubicin and Cytarabine to Induced Human Pluripotent Stem Cell-Derived Cardiomyocytes

Marie C. Fortin, Andrew LaCroix, Qi Wang, Ronald S. Cheung

Blood (2021) 138 (Supplement 1): 4352.

https://doi.org/10.1182/blood-2021-147993

Published: 2021

Journal Articles

Purine Nucleoside Analogs Plus Rituximab Is an Effective Treatment Choice for Hairy Cell Leukemia-Variant: Results from a Single Center in China

Tingyu Wang, Yi Wang, Ru Li, Ying Yu, Jiawen Chen, Rui Lyu, Wenjie Xiong, Qi Wang, Wei Liu, Wenyang Huang, Weiwei Sui, Gang An, Yan Xu, Dehui Zou, Jianxiang Wang, Lugui Qiu, Shuhua Yi

Blood (2021) 138 (Supplement 1): 3547.

https://doi.org/10.1182/blood-2021-150141

Published: 2021

Journal Articles

Allogeneic-Hematopoietic Stem Cell Transplantation Is Effective and Safe for Relapsed/ Refractory B-ALL Patients Who Cannot Get Remission or MRD Negative after CART Treatment

Yanzhi Song, Zhihui Li, Yongqiang Zhao, Fan Yang, Erhui Yuan, Qi Wang, Tong Wu

Blood (2021) 138 (Supplement 1): 1843.

https://doi.org/10.1182/blood-2021-146357

Published: 2021

Journal Articles

Rituximab Maintenance Benefits Less for Follicular Lymphoma Patients with Low Risk of the Follicular Lymphoma International Index

Tingyu Wang, Ru Li, Rui Lv, Ying Yu, Jiawen Chen, Wenjie Xiong, Qi Wang, Wei Liu, Wenyang Huang, Weiwei Sui, Gang An, Yan Xu, Dehui Zou, Jianxiang Wang, Lugui Qiu, Shuhua Yi, Yi Wang

Blood (2021) 138 (Supplement 1): 3544.

https://doi.org/10.1182/blood-2021-147114

Published: 2021

Journal Articles

Pparα Ablation Suppresses T Cell Responses and Anti-Tumor Immunity By Compromising the Antigen-Presenting Properties of Tumor-Associated Macrophages

Anthos Christofides, Carol Cao, Qi Wang, Natalia M Tijaro-Ovalle, Eirini Konstantinidou, Rushil Shah, Chinmay Jani, Rinku Pal, Halil-Ibrahim Aksoylar, Nikolaos Patsoukis, Vassiliki A Boussiotis

Blood (2021) 138 (Supplement 1): 438.

https://doi.org/10.1182/blood-2021-149071

Published: 2021

Journal Articles

Phase 1b Study of Lower-Dose CPX-351 Plus Venetoclax As First-Line Treatment for Patients with AML Who Are Unfit for Intensive Chemotherapy: Preliminary Safety and Efficacy Results

Geoffrey L. Uy, Vinod A. Pullarkat, Praneeth Baratam, Robert K. Stuart, Stefan Faderl, Vijayalakshmi Chandrasekaran, Qi Wang, Divya Chakravarthy, Ronald S. Cheung, Tara L. Lin

Blood (2021) 138 (Supplement 1): 2316.

https://doi.org/10.1182/blood-2021-148455

Published: 2021

Journal Articles

Minimal Residual Disease Assessment Is an Independent Prognostic Factor in Splenic Marginal Zone Lymphoma

Ryu Lv, Yi Wang, Tingyu Wang, Xiong Wenjie, Huijun Wang, Yuting Yan, Qi Wang, Wei Liu, Gang An, MD PhD, Wenyang Huang, Weiwei Sui, MD, Yan Xu, MD, Zhen Yu, MD, Dehui Zou, MD, Jianxiang Wang, MD, Lugui Qiu, MD, Shuhua Yi, MD

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-138592

Published: 2020

Journal Articles

CPX-351 Population Pharmacokinetics in Pediatric and Adult Patients with Acute Myeloid Leukemia (AML)

Qi Wang, Todd M. Cooper, DO, Michael J. Absalon, E. Anders Kolb, MD, Grygoriy Vasilinin, Nathalie H. Gosselin, Todd A. Alonzo, PhD, J.F. Marier

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-137163

Published: 2020

Journal Articles

CPX-351 Exposure-Response Analyses for Efficacy and Safety in Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Qi Wang, Nathalie H. Gosselin, Michael J. Absalon, E. Anders Kolb, MD, J.F. Marier, Todd A. Alonzo, PhD, Stefan Faderl, Todd M. Cooper, DO

Blood (2020) 136 (Supplement 1): 3.

https://doi.org/10.1182/blood-2020-137205

Published: 2020

Journal Articles

IL10RA modulates crizotinib sensitivity in NPM1-ALK + anaplastic large cell lymphoma

Blood (2020) 136 (14): 1657–1669.

https://doi.org/10.1182/blood.2019003793

Published: 2020

Includes: Supplemental data

NARROW

Venetoclax Combining with Homoharringtonine，Daunorubicin and Cytarabine (HAD) As Induction Treatment in Newly Diagnosed Adult Acute Myeloid Leukemia Patients

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

The Incidence, Clinical Application and Prognostic Significance of MYD88 and CXCR4 Mutation in Chinese Patients with Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia

The Prognostic Impact of Measurable Residual Disease Dynamics in Mantle Cell Lymphoma

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

Population Pharmacokinetic-Pharmacodynamic Modeling of Neutrophil and Platelet Count for Lower-Intensity Therapy of CPX-351 Combined with Venetoclax in Acute Myeloid Leukemia

Good Survival of CAR-T Cell Therapy Bridging to Allo-HSCT for Relapsed/Refractory Ph-Positive B-Cell Acute Lymphoblastic Leukemia

First-in-Human Study of Elvn-001, a Highly Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients with Chronic Myeloid Leukemia Who Failed Previous Tyrosine Kinase Inhibitor Therapies

Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK + anaplastic large cell lymphoma

CPX-351, a Dual-Drug Liposomal Formulation, Alleviates the Cardiotoxicity of Daunorubicin and Cytarabine to Induced Human Pluripotent Stem Cell-Derived Cardiomyocytes

Purine Nucleoside Analogs Plus Rituximab Is an Effective Treatment Choice for Hairy Cell Leukemia-Variant: Results from a Single Center in China

Allogeneic-Hematopoietic Stem Cell Transplantation Is Effective and Safe for Relapsed/ Refractory B-ALL Patients Who Cannot Get Remission or MRD Negative after CART Treatment

Rituximab Maintenance Benefits Less for Follicular Lymphoma Patients with Low Risk of the Follicular Lymphoma International Index

Pparα Ablation Suppresses T Cell Responses and Anti-Tumor Immunity By Compromising the Antigen-Presenting Properties of Tumor-Associated Macrophages

Phase 1b Study of Lower-Dose CPX-351 Plus Venetoclax As First-Line Treatment for Patients with AML Who Are Unfit for Intensive Chemotherapy: Preliminary Safety and Efficacy Results

Minimal Residual Disease Assessment Is an Independent Prognostic Factor in Splenic Marginal Zone Lymphoma

CPX-351 Population Pharmacokinetics in Pediatric and Adult Patients with Acute Myeloid Leukemia (AML)

CPX-351 Exposure-Response Analyses for Efficacy and Safety in Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

IL10RA modulates crizotinib sensitivity in NPM1-ALK + anaplastic large cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only